News Quartet of biotechs join Nasdaq after stellar IPOs Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
News BlossomHill, Vogenx and Latigo reveal IPO plans Three more biotechs have revealed their intentions to list on Nasdaq - BlossomHill, Vogenx, and Latigo - as 2026 heads for a record IPO haul.
News SanegeneBio raises $110m for RNAi, plus other financings Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.
R&D Boosting biotech in Basel – with Valentina Francia pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.